Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

KN-93 Phosphate

🥰Excellent
Catalog No. T2606Cas No. 1913269-12-1

KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.

KN-93 Phosphate

KN-93 Phosphate

🥰Excellent
Purity: 99.97%
Catalog No. T2606Cas No. 1913269-12-1
KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.
Pack SizePriceAvailabilityQuantity
1 mg41 €In Stock
5 mg93 €In Stock
10 mg139 €In Stock
25 mg282 €In Stock
50 mg525 €In Stock
100 mg758 €In Stock
500 mg1.510 €In Stock
1 mL x 10 mM (in DMSO)134 €In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "KN-93 Phosphate"

Select Batch
Purity:99.97%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.
Targets&IC50
CaMK II:0.37 μM(Ki)
In vitro
METHODS: PCI2h cells were treated with KN-93 (0, 1, 2, 5, 10 μM) and dopamine content was measured.
RESULTS KN-93 reduced dopamine (DA) content in a dose-dependent manner. [3]
METHODS: Human hepatic stellate cells (LX-2) were treated with KN-93 (0-50 μM), cell proliferation was detected by CCK-8 method, and the expression of two cell cycle regulators, p53 and p21, was detected by SDS-PAGE and Western blotting.
RESULTS KN-93 (5-50 μM) reduced the proliferation of human hepatic stellate cells in a dose-dependent manner, from 81.76% to 27.15% after 24 hours of treatment; 10 μM KN-93 incubation induced a time-dependent decrease in cell growth, from 78.27% at 8 h to 11.48% at 48 h; cell cycle regulator expression analysis showed that KN-93 reduced the expression of p53 and p21. [5]
In vivo
METHODS: 6-hydroxydopamine (OHDA) injection induced PD model in rats, and different doses of KN-93 (1 μg, 2 μg, or 5 μg) were administered into the striatum of successfully lesioned rats before L-DOPA treatment. Abnormal involuntary movement (AIM) scores and apomorphine-induced rotations were measured in PD rats. Phosphorylation level of GluR1 at Serine-845 (pGluR1S845) level was determined by western blot. Arc and Penk levels were measured by real-time polymerase chain reaction (PCR).
RESULTS Both 2 μg and 5 μg KN-93 treatment reduced the AIMs scores of L-dopa-induced PD rats without affecting the anti-parkinsonian effect of L-dopa; consistent with behavioral analysis, KN-93 (2 μg) treatment reduced the level of pGluR1S845 in PD rats and also reduced the expression of Gad1 and Nur77 in PD rats. [1]
METHODS: KN-93 (0.24 mg/kg, intraperitoneal injection, three times a week) treated MRL/lpr Foxp3-GFP mice, harvested lymphoid organs, and determined the number of Foxp3 cells; from MRL/lpr Foxp3-GFP mice Naïve CD4 cells were isolated from the spleen and cultured in vitro under Treg polarizing conditions to determine whether they could prevent disease progression.
RESULTS Treg cells in PBS-treated mice gradually decreased, while Treg cells in KN-93-treated mice remained stable and significantly increased; more GFP-positive cells were found in the spleen and peripheral lymph nodes of KN-93-treated mice. ; The percentage of Treg cells was higher in the presence of KN-93 in a dose-dependent manner. [2]
Chemical Properties
Molecular Weight599.03
FormulaC26H32ClN2O8PS
Cas No.1913269-12-1
SmilesOP(O)(O)=O.COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 93 mg/mL (155.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 84 mg/mL (140.2 mM)
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM1.6694 mL8.3468 mL16.6937 mL83.4683 mL
5 mM0.3339 mL1.6694 mL3.3387 mL16.6937 mL
10 mM0.1669 mL0.8347 mL1.6694 mL8.3468 mL
20 mM0.0835 mL0.4173 mL0.8347 mL4.1734 mL
50 mM0.0334 mL0.1669 mL0.3339 mL1.6694 mL
100 mM0.0167 mL0.0835 mL0.1669 mL0.8347 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy KN-93 Phosphate | purchase KN-93 Phosphate | KN-93 Phosphate cost | order KN-93 Phosphate | KN-93 Phosphate chemical structure | KN-93 Phosphate in vivo | KN-93 Phosphate in vitro | KN-93 Phosphate formula | KN-93 Phosphate molecular weight